¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gradient induced phase shift effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • resonance effect
    °ø¸íÈ¿°ú
  • radioactive effect
    ¹æ»ç´ÉÈ¿°ú
  • reversing effect
    ¿ªÀüÈ¿°ú
  • stochastic effect
    È®·üÈ¿°ú
  • suction effect
    Èí¼öÈ¿°ú
  • summation effect
    °¡ÁßÈ¿°ú
  • synergistic effect
    »ó½ÂÈ¿°ú
  • shielding effect
    Â÷ÆóÈ¿°ú, °¡¸²È¿°ú
  • shunt effect
    Áö¸§±æÈ¿°ú, ¼ÇƮȿ°ú
  • side effect
    ºÎÀÛ¿ë
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • active phase
    Ȱ¼º±â
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • late effect
    ¸¸±âÈ¿°ú, ÈÄÀ¯È¿°ú
  • latitude effect
    À§µµÈ¿°ú
  • magnetic field effect
    ÀÚ±âÀåÈ¿°ú
  • magnetization transfer effect
    ÀÚ±âÈ­Àü´ÞÈ¿°ú
  • masking effect
    ÀºÆóÈ¿°ú
  • mass effect
    µ¢ÀÌÈ¿°ú
  • mesomeric effect
    °ø¸íÈ¿°ú
  • nonstochastic effect
    ºñÈ®·ü·ÐÀûÈ¿°ú
  • nonthermal effect
    ºñ¿­È¿°ú
  • oblique angle effect
    »ç°¢È¿°ú
  • obliquity effect
    ±â¿ï±âÈ¿°ú
  • on-off effect
    °³½ÃÁ¾·áÈ¿°ú
  • osmolality effect
    ¸ô¶ö»ïÅõ¾ÐÈ¿°ú
  • overkill effect
    °úÀ×Ä¡»çÈ¿°ú
  • palliative effect
    °í½ÄÀûÈ¿°ú, °æ°¨È¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • phase I block
    Á¦1»óÂ÷´Ü.
  • phase advance
    »óÀüÁø(ßÓîñòä)
  • phase angle
    À§»ó°¢(êÈßÓÊÇ).
  • phase angle
    À§»ó °¢
  • phase artifact
    À§»ó Àΰø¹°
  • phase axis
    ˤȗ ̈
  • phase boundary
    »ó°è(Ë×Ë­).
  • phase boundary force
    »ó°è(Àü)·Â(ßÓÍ£ ï³æ³).
  • phase boundary potential
    »ó°èÀüÀ§(ßÓÍ£ ï³êÈ).
  • phase coherence
    À§»ó °áÁý
  • phase conjugate symmetry
    À§»ó ȸº¹ ´ëĪ (À§»ó °ø¾× ´ëĪ)
  • phase constant
    À§»ó»ó¼ö(êÈßÓßÈâ¦).
  • phase contrast
    À§»ó ´ëÁ¶
  • phase contrast (PC) MR angiography
    À§»ó ´ëÁ¶ ÀÚ±â°ø¸í Ç÷°üÁ¶¿µ¼ú
  • phase contrast microscopy
    À§»óÂ÷(êÈßÓó¬)Çö¹Ì°æ°Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • opioid-induced disorder
    ¾ÆÆí¾çÁ¦Á¦ À¯µµ¼ºÀå¾Ö(ë¯Óôàõî¡äô)(º´)
  • peak gradient strength
    ÃÖ°í °æ»ç ¼¼±â
  • physician induced demand
    ÀÇ»çÀ¯¹ß ÀÇ·á¼ö¿ä.
  • potential gradient
    Àü¾Ð°æ»ç, ÀüÀ§°æ»ç.
  • pressure gradient
    ¾Ð·Â°æ»ç.
  • pressure gradient
    ¾Ð·Â°æ»ç
  • pulsed gradient spin echo (PGSE)
    ÆÞ½º °æ»ç ½ºÇÉ ¿¡ÄÚ
  • radiation induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • radiation-induced
    ¹æ»ç¼±À¯¹ßÀÇ
  • read gradient
    ÆÇµ¶ °æ»çµµ
  • receptor gradient
    ¼ö¿ëü°æ»ç.
  • rectal bleeding, radiation induced
    ¹æ»ç¼±À¯¹ß Á÷ÀåÃâÇ÷
  • rephasing gradient motion
    ÀçÀ§»ó °æ»ç ¿îµ¿
  • reversal of gradient
    °æ»ç¿ªÀü.
  • rewinder gradient
    µÇ°¨±â °æ»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
DEFT dose-effect factor for tumor
eff effect; efferent; efficiency; effusion
effect effective
FAE fetal alcohol effect
FET field-effect transistor; forced expiratory time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
PEV Position effect variegation
PAE Post Antibiotic Effect
PAFE Post-antifungal effect
PNEC Predicted No Effect Concentration
RERF Radiation Effect Research Foundation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ration effect
    ¹æ»ç¼± È¿°ú
  • resonance effect
    °ø¸í È¿°ú
  • reverse piezoelectric effect
    ¿ª¾ÐÀü È¿°ú
  • RF antennae effect
    °íÁÖÆÄ ¾ÈÅ׳ª È¿°ú
  • second influencing effect
    ÀÌÂ÷ È¿°ú
  • sedative effect
    ÁøÁ¤ È¿°ú
  • sensory effect
    °¨°¢ È¿°ú
  • shearing effect
    Àü´Ü È¿°ú
  • shimmering effect : ÈíÀÎ ½Ã ÄÝ·¹½ºÅ×·ÑÀÌ °áÁ¤ÀÌ Æ÷ÇԵǾî ÀÖ´Â ¿¯Àº ¹Ð¤ »öÀÇ ¾×ü°¡ ³ª¿À¸ç ÀÌ ÄÝ·¹½ºÅ×·Ñ °áÁ¤Àº À¯¸®°ü¿¡ ³»¿ë¹°ÀÎ ¾×ü¸¦ ³Ö¾î ±¤¼± ¾Æ·¡¿¡¼­ ºñÃ纸¸é Ư¡ÀûÀÎ ºûÀ» ³»´Â Çö»ó.

    shimming

    º¸Á¤
  • sialogogic effect
    Ÿ¾× ºÐºñ ÃËÁø È¿°ú
  • side effect
    ºÎÀÛ¿ë
    »ç¿ëµÈ ¾àǰÀ̳ª ¾àÁ¦°¡ ¸ñÀû ÀÌ¿ÜÀÇ ´Ù¸¥ °á°ú, Áï ¹Ý´ë ÀÛ¿ëÀ¸·Î ¾à¹°¿¡ ´ëÇÑ À¯ÇØ ÀÛ¿ë, ƯÈ÷ ±× Åõ¿©·Î È¿´ÉÀ» Ãß±¸ÇÏ´Â °Í°ú ´Ù¸¥ Á¶Á÷À̳ª ±â°ü °èÅë¿¡ ¹ÌÄ¡´Â ÇØ·Î¿î ¿µÇâ°ú °°Àº °Í.
  • siphonage effect
    ½ÎÀÌÆù È¿°ú
  • snow-storm effect
    ´«º¸¶ó È¿°ú
  • somogyi effect
    ¼Ò¸ð±â È¿°ú
    Á¦ 1Çü ´ç´¢º´ ȯÀÚ¿¡¼­ ¾ß°£¿¡ ÀúÇ÷´çÁõÀÌ ¹ß»ýÇÏ´Â °æ¿ì ±æÇ× Á¶Àý È£¸£¸óÀÇ ºÐºñ¸¦ ÀÚ±ØÇÏ¿©
  • stochastic effect
    È®·üÀû È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
Zeeman effect The splitting of spectral lines into three or more symmetrically placed lines when the light source is subjected to a magnetic field.
(05 Mar 2000)
Fenn effect The increased liberation of heat in a stimulated muscle when it is allowed to do mechanical work; the amount of heat liberated is increased in proportion to the distance the muscle is allowed to shorten and in proportion to the tension it must develop (e.g., the weight it lifts) during shortening; thus increased chemical energy is consumed both to liberate increased heat and to do increased mechanical work.
(05 Mar 2000)
zygotic effect gene <genetics> A gene whose phenotype is dependent on the genotype of the zygote, rather than the genotype of the mother.
See: maternal effect gene.
(18 Nov 1997)
late effect Side effects of chemotherapy and/or radiotherapy which only become apparent with long-term monitoring of the patient over a period of years. These are of particular concern in patients below the age of puberty.
(18 Nov 1997)
founder effect The establishment of a new population by a few original founders (in an extreme case, by a single fertilized female) which carry only a small fraction of the total genetic variation of the parental population [Ernst Mayr, 1963]. The result is that a given allele, gene, chromosome, or part of a chromosome found in members of the population can be traced back to one ancestral individual.
(09 Oct 1997)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acceleration phase <cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes.
After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase).
(15 Jan 1998)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acute-phase reaction <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms.
It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors.
(12 Jul 2000)
anal phase In psychoanalytic personality theory, the stage of psychosexual development, occurring when a child is between 1 and 3 years, during which activities, interests, and concerns are centreed around the anal zone.
(05 Mar 2000)
aqueous phase The water portion of a system consisting of two liquid phase's, one mainly water, the other a liquid immiscible with water (e.g., benzene, ether).
(05 Mar 2000)
blast phase Refers to advanced chronic myelogenous leukaemia. In this phase, the number of immature, abnormal white blood cells in the bone marrow and blood is extremely high. Also called blast crisis.
(12 Dec 1998)
g0 phase Phase of the cell cycle where cells exist in a quiescent state. These cells have unduplicated DNA, degraded RNA and protein, and low enzyme activity. The ability to switch between g0 and g1 (and vice versa) determines the post-embryonic cell proliferation rate and is defectively controlled in neoplastic cells.
(12 Dec 1998)
g1 phase <cell biology, molecular biology> The period during interphase in the cell cycle between mitosis and the S phase (when DNA is replicated).
Also known as the decision period of the cell, because the cell decides to divide when it enters the s phase. The G stands for gap.
(09 Oct 1997)
g2 phase <cell biology, molecular biology> The period during interphase in the cell cycle between the S phase (when DNA is replicated) and mitosis (when the nucleus, then cell, divides).
at this time, the cell checks the accuracy of DNA replication and prepares for mitosis. The G stands for gap.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á